Workflow
人用创新药
icon
Search documents
申联生物: 关于参股公司UB-221创新药II期临床研究进展的自愿性披露公告
Zheng Quan Zhi Xing· 2025-08-31 10:13
Group 1 - The company has received an update on the progress of the innovative drug UB-221's Phase II clinical research from its associate company, Yangzhou Shizhi Source Biotechnology Co., Ltd. [1] - UB-221 is a humanized monoclonal antibody developed by the inventor of the anti-IgE therapy, Dr. Zhang Ziwen, and is designed to treat allergic reactions by neutralizing free IgE and inhibiting its synthesis [2][1]. - The ongoing Phase II clinical trial is a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of UB-221 in patients with chronic spontaneous urticaria (CSU), with a target enrollment of 144 patients, ultimately recruiting 145 [2]. Group 2 - The company is focused on building a world-class high-tech biopharmaceutical company and is actively expanding its business into the human innovative drug sector, leveraging its diverse biopharmaceutical technology platforms and talent reserves [3]. - The company is advancing the development of three innovative drugs: UB-221, UB-421, and UB-621, while also exploring new indications, supported by its technological expertise in synthetic peptides, genetic engineering, and mRNA [3].
申联生物2024年营收3.03亿元 宠物用生物制品研发获突破
Core Viewpoint - The company reported a revenue of 303 million yuan in 2024, a year-on-year increase of 0.64%, but faced a net loss of 44.74 million yuan, marking its first loss since going public due to intensified competition in the animal health industry and declining vaccine prices [1] Group 1: Financial Performance - The company achieved a revenue of 303 million yuan in 2024, reflecting a growth of 0.64% compared to the previous year [1] - The net profit attributable to shareholders was a loss of 44.74 million yuan, which is the first loss since the company was listed [1] - The decline in gross margin was attributed to increased competition and lower prices for vaccine products, despite an increase in product sales [1] Group 2: Product Development and Market Strategy - The company is focused on expanding its market share in the government procurement sector and enhancing its presence in the pig vaccine market while also developing the ruminant vaccine market and improving its pet biological product offerings [1] - In the pig vaccine segment, several products are in the approval process, including vaccines for porcine infectious pleuropneumonia and porcine reproductive and respiratory syndrome [1] - The company has made significant progress in developing new pet biological products, including a long-acting recombinant canine alpha interferon and mRNA vaccines [2] Group 3: Research and Development - The company invested 85.99 million yuan in R&D in 2024, with a notable acceleration in the conversion of research results, filing 28 national patent applications and obtaining 2 new veterinary drug registration certificates [2] - The company’s animal inactivated vaccine workshop has passed GMP certification, and the construction of production lines for live vaccines and mRNA vaccines is progressing steadily [2] Group 4: Expansion into Human Medicine - The company is leveraging its technology platform to explore opportunities in the human medicine sector, establishing a subsidiary focused on innovative drugs and investing in a company specializing in human monoclonal antibodies [3] - The company plans to commercialize the sale of experimental pigs to support its product development efforts [3]